During the past decade, HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 11 clinical trials were completed, i.e. on average, 64.7% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "HealthCore-NERI" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Atea Pharmaceuticals, Inc." with 1 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Incyte Corporation" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas" are "COVID-19" (2 trials), "COVID-19 Pneumonia" (2 trials), "Crohn's Disease" (2 trials), "Respiratory Syncytial Virus Infections" (2 trials) and "Type 2 Diabetes" (2 trials). Many other conditions were trialed in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas" in a lesser frequency.

Most popular intervention types in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas" are "Drug" (21 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Baricitinib" (2 trials), "Mirikizumab" (2 trials), "dabigatran etexilate" (2 trials) and "Cabozantinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas" are 24 trials for "All" genders.

Currently, there are NaN active trials in "HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".